ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Johnson & Johnson has purchased Numab’s investigational antibody treatment for atopic dermatitis for about $1.25 billion. Atopic dermatitis, the most common form of eczema, causes painful itching and dry skin. J&J says this antibody, called NM26, targets two pathways that lead to inflammation and itching. It also says NM26 could be used to treat other skin conditions that arise from the same inflammation pathway. NM26 is ready to begin Phase 2 trials, according to J&J.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X